Large-scale screening for somatic mutations in lung cancer

Rosell, Rafael; Karachaliou, Niki

doi:10.1016/s0140-6736(15)01125-3

Cited by 111 publications

(75 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The two most important alterations in the carcinogenesis of the lung are somatic mutations in the epidermal growth factor receptor (EGFR) and KRAS proto-oncogene, GTPase (KRAS) genes (4). These mutations are more frequent in lung adenocarcinoma than in SCC (5) and have implications for treatment selection.…”

mentioning

confidence: 99%

KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients

Garzón¹,

Villatoro²,

Teixidó³

et al. 2016

Transl. Lung Cancer Res.

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 99%

KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients

Garzón¹,

Villatoro²,

Teixidó³

et al. 2016

Transl. Lung Cancer Res.

Self Cite

View full text Add to dashboard Cite

“…During the past 10 years, thanks to the technological advances, our knowledge on NSCLC tumor biology has improved (7). Different driver molecular alterations, responsible for the development of oncogene-addicted NSCLC tumors, have been identified, especially in the subgroup of patients with adenocarcinoma (8–12).…”

Section: Introductionmentioning

confidence: 99%

Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer

et al. 2017

View full text Add to dashboard Cite

Innovative therapeutic agents have significantly improved outcome with an acceptable safety profile in a substantial proportion of non-small cell lung cancer (NSCLC) patients, who depend on oncogenic molecular alterations for their malignant phenotype. Despite the survival improvement achieved with first-line chemotherapy, about 30% of patients do not obtain a tumor response. Moreover, those patients, initially sensitive to treatment, acquire resistance and develop tumor progression after a median of about 5 months. Approximately 60% of the patients progressing from first-line chemotherapy receive further systemic treatment in the second-line setting. Moreover, new options have emerged in the second-line armamentarium for the treatment of patients with NSCLC, including immune checkpoint inhibitors and antiangiogenic agents. The current review provides an overview on the clinical studies that gained the approval of chemotherapy agents (docetaxel and pemetrexed) and epidermal growth factor receptor gene–tyrosine kinase inhibitors as second-line treatment options for NSCLC patients, not carrying molecular alterations.

show abstract

“…Many targeted therapies that inhibit genetic alterations, required to stop tumor growth and metastasis, have demonstrated proven activity in patients with lung adenocarcinoma (1,2). The use of matched therapy is strongly related to the level of evidence that the identified mutation can really predict response to the treatment.…”

Section: Introductionmentioning

confidence: 99%

“…The presence of KRAS mutations is usually associated with the use of tobacco (1,45,46). Co-occurring genetic alterations in STK11 (LKB1), TP53 and CDKN2A/ B can define three major subgroups of KRAS mutant lung adenocarcinoma with distinct response to immunotherapy.…”

Section: Introductionmentioning

confidence: 99%